BRKR

Bruker has been on fire lately. In the past six months alone, the company’s stock price has rocketed 50.7%, reaching $58.84 per share. This run-up might have investors contemplating their next move.

Bruker (NasdaqGS:BRKR) and Charité have released a draft atlas of the human plasma proteome at proteoform resolution. The project maps more than 179,000 distinct plasma proteoforms, using Bruker's timsTOF mass spectrometry platform as a core technology.

Bruker (BRKR) just rolled out new timsUltra AIP and timsOmni workflows, extending its mass spectrometry platform into deeper protein sequencing, glycopeptide analysis, structural proteomics, and oligonucleotide characterization, which could matter for long…

BRKR shares surge 66.3% in a year, fueled by strong demand in mass spectrometry and biopharma, despite restructuring challenges and currency headwinds.

Investors need to pay close attention to BRKR stock based on the movements in the options market lately.

Bruker (NASDAQ:BRKR) CFO Gerald Herman said the company’s second-quarter results reflected stronger-than-expected organic order bookings and earnings per share, while revenue came in later than anticipated.

Bruker Corporation previously announced a multi-system order worth more than US$6.00 million from the University of California, Berkeley to equip the Pines Magnetic Resonance Center with next-generation high-field NMR instrumentation, including an AV NEO-X 800 MHz spectrometer with a cryogenically cooled MAS CryoProbe and multiple supporting systems, scheduled for delivery in 2027.